Growth Stocks To Keep An Eye On – September 23rd

Circle Internet Group, Novo Nordisk A/S, and Scholar Rock are the three Growth stocks to watch today, according to MarketBeat’s stock screener tool. Growth stocks are shares of companies whose revenues and earnings are expected to grow at an above-average rate compared to the overall market. These companies typically reinvest most of their profits into expansion, research and development, or new projects rather than paying dividends. As a result, growth stocks often carry higher price-to-earnings ratios and offer the potential for significant capital appreciation, albeit with greater volatility. These companies had the highest dollar trading volume of any Growth stocks within the last several days.

Circle Internet Group (CRCL)

Founded in 2013, Circle’s mission is to raise global economic prosperity through the frictionless exchange of value. We intend to connect the world more deeply by building a new global economic system on the foundation of the internet, and to facilitate the creation of a world where everyone, everywhere can share value as easily as we can today share information, content, and communications.

Novo Nordisk A/S (NVO)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Scholar Rock (SRRK)

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.